EDAP Announces Focal One® HIFU Sale to Foch Hospital, Paris
December 14 2016 - 8:55AM
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
ultrasound, today announced the sale of a Focal One® system to Foch
Hospital, Paris, one of the largest private hospitals in the Paris
Area.
Pr. Thierry Lebret, Head of Urology and Kidney Transplantation
Department at Foch Hospital and recently appointed President of the
French Urology Association, commented: "Our team is enthusiastic
about the acquisition of Focal One HIFU as it responds to a growing
demand for more non-invasive prostate cancer treatments. This
innovative system adds to our portfolio of solutions offered to
prostate cancer patients. Focal One combines state-of-the-art IRM
and real-time ultrasound imaging capabilities with targeted HIFU
technology to allow precise ablation of prostatic tissue, with
reduced side effects."
Pierre Reboul, EDAP TMS France Business Unit Director, added:
"We are very pleased with this Focal One acquisition by the
prominent Foch Hospital under the leadership of Pr. Lebret. This
investment confirms the growing adoption of HIFU for the management
of prostate cancer in France as demonstrated during the recent
French Urology Association Congress held in Paris last November.
Our HIFU Club, organized during this event, gathered more than 50
French Focal One users who shared their experience and appetite for
the technology’s capabilities. We look forward to continued
expansion of HIFU access to more prestigious centers in
France."
Marc Oczachowski, EDAP's Chief Executive Officer, concluded:
"Interest in our innovative HIFU technologies is clearly growing as
we continue to open and train new state-of-the-art and academic
centers in France and internationally. In addition, it supports our
belief that Focal One has the potential to become a primary
therapeutic option in modern prostate cancer management."
About EDAP TMS SA
EDAP TMS SA markets today Ablatherm® for high-intensity focused
ultrasound (HIFU) for prostate tissue ablation in the U.S. and for
treatment of localized prostate cancer in the rest of the world.
HIFU treatment is shown to be a minimally invasive and effective
option for prostatic tissue ablation with a low occurrence of side
effects. Ablatherm-HIFU is generally recommended for patients with
localized prostate cancer (stages T1-T2) who are not candidates for
surgery or who prefer an alternative option, or for patients who
failed radiotherapy treatment. Ablatherm-HIFU is approved for
commercial distribution in Europe and some other countries
including Mexico and Canada, and has received 510(k) clearance by
the U.S. FDA. The Company also markets an innovative robot-assisted
HIFU device, the Focal One®, dedicated to focal therapy of prostate
cancer. Focal One® is CE marked but is not FDA approved. The
Company also develops its HIFU technology for the potential
treatment of certain other types of tumors. EDAP TMS SA also
produces and distributes medical equipment (the Sonolith®
lithotripters’ range) for the treatment of urinary tract stones
using extra-corporeal shockwave lithotripsy (ESWL) in most
countries including Canada and the U.S. For more information on the
Company, please visit http://www.edap-tms.com, and
http://www.hifu-planet.com.
Forward-Looking Statements
In addition to historical information, this press release may
contain forward-looking statements. Such statements are based on
management’s current expectations and are subject to a number of
risks and uncertainties, including matters not yet known to us or
not currently considered material by us, and there can be no
assurance that anticipated events will occur or that the objectives
set out will actually be achieved. Important factors that could
cause actual results to differ materially from the results
anticipated in the forward-looking statements include, among
others, the clinical status and market acceptance of our HIFU
devices and the continued market potential for our lithotripsy
device. Factors that may cause such a difference also may include,
but are not limited to, those described in the Company’s filings
with the Securities and Exchange Commission and in particular, in
the sections "Cautionary Statement on Forward-Looking Information"
and "Risk Factors" in the Company’s Annual Report on Form 20-F.
Contact:
Blandine Confort
Investor Relations / Legal Affairs EDAP TMS SA
+33 4 72 15 31 72
bconfort@edap-tms.com
Investors:
CG CAPITAL
877.889.1972
investorrelations@cg.capital
www.cg.capital
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024